---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-006354"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T17:05:28.195130+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oragenics licenses Inspirevax intranasal adjuvant BDX301 for COVID-19 vaccine candidate NT-CoV2-1

## Summary
- Upfront fee $50K; milestones up to $5.3M including $2M on first US sale; tiered royalties 7% net sales (decreasing to 4%).
- Development milestones: first patient in clinical study by Dec 31, 2023; Phase 2a by Sep 30, 2024; Phase 3 by Dec 31, 2026; marketing app by Jun 30, 2028.
- Preclinical GLP toxicology study in rabbits showed no toxicity signals or adverse events for NT-CoV2-1 plus BDX301.
- Companies to form Joint Development Committee; option to expand collaboration to other intranasal vaccine candidates.
- Oragenics to provide program update in mid-2023.

## SEC filing metadata
- accession: 0001493152-23-006354
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315223006354/0001493152-23-006354-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315223006354/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-006354
- JSON: https://secwatch.observer/filing/0001493152-23-006354.json
- Plain text: https://secwatch.observer/filing/0001493152-23-006354.txt

## Key facts
- Material Agreements
  ORAGENICS INC entered into License Agreement with Inspirevax Inc. valued at $50,000 (effective 2023-02-23).
  - Action: entry
  - Agreement: license
  - Counterparty: Inspirevax Inc.
  - Value: $50,000
  - Effective: 2023-02-23
  source text: On February 23, 2023, the Company entered into a Commercial License Agreement (the “License Agreement”) with Inspirevax Inc. (“Inspirevax”) pursuant to which Inspirevax granted the Company an exclusive worldwide license to use Inspirevax’s inventions, patents, trade secrets, know-how, copyright, biological material, designs, and/or technical information created by or on behalf of Inspirevax (the “Inspirevax Technologies”) relating to its novel lipid-protein based intranasal adjuvants, to make, research, and develop an intra-nasal vaccine in combination with an antigen (“Combination Product”) to be used in an intranasal vaccine for use against diseases caused by coronaviruses and any genetic variants thereof to be sold by us. As consideration for the grant of the license, the Company will pay an upfront signing fee of $50,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1174940/000149315223006354/0001493152-23-006354-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.